{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-031794","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2023-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.760929+00:00","generated_at":"2026-06-13T15:33:06.271887+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Roivant Q4/FY2023: VTAMA net rev $13.7M, $28.0M FY; RVT-3101 UC data positive; cash $1.7B; FY loss $1.23B","bullets":["VTAMA net product revenue $13.7M in Q4, $28.0M FY; 170k prescriptions since launch; 76% US commercial lives covered.","RVT-3101 improved efficacy from week 14 to week 56 in Phase 2b UC study; Phase 2 Crohn's initiated, data expected Q4 2024.","VTAMA met primary and all secondary endpoints in Phase 3 ADORING 1/2 for atopic dermatitis in 813 patients including children aged 2+.","Cash and equivalents $1.7B at March 31, 2023; cash runway into H2 2025. GAAP loss from continuing ops $175M Q4 ($0.20/share).","FY2023 GAAP loss from continuing ops $1.23B ($1.58/share); net loss attributable to Roivant $1.01B."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-031794","json":"https://secwatch.observer/filing/0001140361-23-031794.json","markdown":"https://secwatch.observer/filing/0001140361-23-031794.md","text":"https://secwatch.observer/filing/0001140361-23-031794.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123031794/0001140361-23-031794-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123031794/brhc20054989_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T15:33:06.271887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"917aec2fa243dc7b8b7f26fbd75152339f6125a6","claim":"Roivant Sciences Ltd. reported financial results for the fourth quarter and fiscal year ended March 31, 2023.","evidence_excerpt":"On June 28, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123031794/0001140361-23-031794-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}